Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
ZINGO is an intradermal lidocaine hydrochloride monohydrate delivery system approved in 2007 for rapid-onset local anesthesia. It utilizes a needle-free powder system to deliver lidocaine directly into the dermis, providing fast anesthetic onset without injection. The product is indicated for use prior to minor dermatological procedures, venipuncture, and other needle-based medical interventions.
The product is at peak lifecycle with sustained market presence, though linked job count is zero, indicating a mature, stable team structure.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Efficacy and Safety of Zingo in Chinese Children
ZINGO roles focus on commercial execution and market maintenance in a niche procedural anesthesia segment. The zero linked jobs and stable peak-lifecycle status suggest a lean, mature team structure with lower hiring velocity and narrower career growth pathways.
Worked on ZINGO at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo